- Home
- PCSA vs SGLY Comparison
PCSA vs SGLY Comparison
Compare PCSA & SGLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCSA
- SGLY
- Stock Information
- Founded
- PCSA 2011
- SGLY 2001
- Country
- PCSA United States
- SGLY United States
- Employees
- PCSA 13
- SGLY N/A
- Industry
- PCSA Biotechnology: Pharmaceutical Preparations
- SGLY
- Sector
- PCSA Health Care
- SGLY
- Exchange
- PCSA Nasdaq
- SGLY Nasdaq
- Market Cap
- PCSA 3.3M
- SGLY 3.9M
- IPO Year
- PCSA N/A
- SGLY 2008
- Fundamental
- Price
- PCSA $0.22
- SGLY $1.03
- Analyst Decision
- PCSA Strong Buy
- SGLY
- Analyst Count
- PCSA 1
- SGLY 0
- Target Price
- PCSA $6.00
- SGLY N/A
- AVG Volume (30 Days)
- PCSA 46.5M
- SGLY 67.2K
- Earning Date
- PCSA 08-12-2025
- SGLY 08-26-2025
- Dividend Yield
- PCSA N/A
- SGLY N/A
- EPS Growth
- PCSA N/A
- SGLY N/A
- EPS
- PCSA N/A
- SGLY N/A
- Revenue
- PCSA N/A
- SGLY $2,172,036.00
- Revenue This Year
- PCSA N/A
- SGLY N/A
- Revenue Next Year
- PCSA N/A
- SGLY N/A
- P/E Ratio
- PCSA N/A
- SGLY N/A
- Revenue Growth
- PCSA N/A
- SGLY N/A
- 52 Week Low
- PCSA $0.15
- SGLY $0.54
- 52 Week High
- PCSA $3.10
- SGLY $7.65
- Technical
- Relative Strength Index (RSI)
- PCSA 44.28
- SGLY 51.57
- Support Level
- PCSA $0.20
- SGLY $1.02
- Resistance Level
- PCSA $0.33
- SGLY $1.16
- Average True Range (ATR)
- PCSA 0.09
- SGLY 0.08
- MACD
- PCSA -0.01
- SGLY -0.01
- Stochastic Oscillator
- PCSA 6.53
- SGLY 50.00
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.